Duchenne muscular dystrophy: Clinical trials and emerging tribulations

Current Opinion in Neurology

Volumn 28, Issue 5, 2015, Pages 542-546

  Shieh, Perry B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; IDEBENONE; MYOSTATIN; PHOSPHODIESTERASE V INHIBITOR;

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DUCHENNE MUSCULAR DYSTROPHY; GENE REPLACEMENT THERAPY; HEART FUNCTION; HUMAN; NONSENSE MUTATION; OUTCOME ASSESSMENT; POPULATION; RARE DISEASE; REVIEW; MUSCULAR DYSTROPHY, DUCHENNE; RARE DISEASES;

CLINICAL TRIALS AS TOPIC; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; RARE DISEASES;

EID: 84941765205     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000243     Document Type: Review

References (36)

1. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2:90-95.
2. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34:135-144.
3. Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30:293-299.
4. Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014; 13:987-996.
5. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013; 74:637-647.
6. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014; 50:477-487.
7. Wagner KR, McPherron AC, Winik N, et al. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002; 52:832-836.
8. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 2015; 23:192-201.
9. Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 2015; 385:1748-1757.
10. Duan D. Duchenne muscular dystrophy gene therapy: Lost in translation? Res Rep Biol 2011; 2011:31-42.
11. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363:1429-1437.
12. Chicoine LG, Montgomery CL, Bremer WG, et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 2014; 22:338-347.
13. Lostal W, Kodippili K, Yue Y, et al. Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther 2014; 25:552-562. Gene therapy.
14. Nelson MD, Rader F, Tang X, et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 2014; 82:2085-2091.
15. Martin EA, Barresi R, Byrne BJ, et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012; 4:162ra55.
16. Das A, Durrant D, Salloum FN, et al. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther 2015; 147:12-21.
17. Leung DG, Herzka DA, Thompson WR, et al. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol 2014; 76:541-549.
18. Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015; 14:153-161.
19. McDonald CM, Henricson EK, Abresch RT, et al. The 6-min walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013; 48:343-356.
20. Goemans N, van den Hauwe M, Wilson R, et al. Ambulatory capacity and disease progression as measured by the 6-min-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord 2013; 23:618-623.
21. Mazzone ES, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009; 19:458-461.
22. De Sanctis R, Pane M, Sivo S, et al. Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscul Disord 2015; 25:14-18.
23. Mayhew A, Cano S, Scott E, et al. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011; 53:535-542.
24. PaneM, Scalise R, Berardinelli A, et al. Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscul Disord 2013; 23:451-455.
25. Connolly AM, Florence JM, Cradock MM, et al. One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. Pediatr Neurol 2014; 50:557-563.
26. Pane M, Mazzone ES, Fanelli L, et al. Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 2014; 24:201-206.
27. Mayhew A, Mazzone ES, Eagle M, et al. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 2013; 55:1038-1045.
28. Griggs RC, Herr BE, Reha A, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 2013; 48:27-31.
29. Anthony K, Arechavala-Gomeza V, Taylor LE, et al. Dystrophin quantification: biological and translational research implications. Neurology 2014; 83:2062-2069.
30. Fischmann A, Hafner P, Fasler S, et al. Quantitative MRI can detect subclinical disease progression in muscular dystrophy. J Neurol 2012; 259:1648-1654.
31. Fischmann A, Hafner P, Gloor M, et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol 2013; 260:969-974.
32. Forbes SC, Willcocks RJ, Triplett WT, et al. Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study. PLoS One 2014; 9:e106435.
33. Bonati U, Hafner P, Schadelin S, et al. Quantitative muscle MRI: a powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Disord 2015 (in press).
34. Arpan I, Willcocks RJ, Forbes SC, et al. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology 2014; 83:974-980.
35. Geisbush TR, Visyak N, Madabusi L, et al. Inter-session reliability of electrical impedance myography in children in a clinical trial setting. Clin Neurophysiol (in press).
36. Rutkove SB, Geisbush TR, Mijailovic A, et al. Cross-sectional evaluation of electrical impedance myography and quantitative ultrasound for the assessment of Duchenne muscular dystrophy in a clinical trial setting. Pediatr Neurol 2014; 51:88-92.